Evaluación del deterioro cognitivo primario en pacientes con nefritis lúpica de Barranquilla (Atl, co)
| datacite.rights | http://purl.org/coar/access_right/c_16ec | spa |
| dc.contributor.advisor | Sánchez Pérez, Freddy | |
| dc.contributor.advisor | González Torres, Henry J. | |
| dc.contributor.author | Pérez Padilla, Mariluz | |
| dc.date.accessioned | 2022-11-23T14:31:09Z | |
| dc.date.available | 2022-11-23T14:31:09Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | La nefritis lúpica y los problemas en el desarrollo cognitivo que presentan los pacientes que la padecen es un problema de salud pública porque el lupus es conocido como una afectación de carácter multiorgánico, entre ellos el sistema nervioso, manifestándose en evento psiquiátricos o deterioro cognitivo. Objetivo: Evaluar la aparición del deterioro cognitivo primario en pacientes diagnosticados con Nefritis Lúpica en Barranquilla (ATL, CO) durante el año 2022. Metodología: Se realizó un censo de los pacientes agremiados en una Fundación de pacientes con NL. Se le aplicó el test MoCA para evaluar el desarrollo de los DCP y este se cruzó con los resultados histopatológicos y sociodemográficos. Se realizaron medidas de asociación tales como Test exacto de Fischer y comparaciones entre grupos con DCP y sin DCP. Resultados: Se evaluaron un total de 30 pacientes que cumplieron los criterios de inclusión y exclusión. La edad promedio fue de 38.11 años, Las clases proliferativas fueron las predominantes (76.67%) El promedio de puntuación MoCA Test fue de 22.6±4.49, El 76.7% de los pacientes presentaron algún grado de DCP; no hubo diferencia entre hombre y mujeres para DPC, ni para la clase histopatológica (p > 0.05). Se evaluó la Escolaridad, Sexo y Edad a través de una regresión simple encontrándose que que ninguno de los tres tuvo una relación con el DCP (p: 0.05). Se observó a través de un ANOVA una diferencia de los 3 niveles de DCP (p: 0.0119), se modelo la concentración de CrSr vs el DCP y se encontró una significación inversa, es decir, entre más aumente la CrSr el puntaje MoCA disminuye, es decir, el DCP es más marcado. Conclusiones: La presencia de DCP en los pacientes con NL es alta en comparación con la proporción de los que no la han desarrollado (7/10). La concentración de CrSr fue el factor determinante para el desarrollo de DCP en los pacientes con NL, es decir que, controlar este parámetro controlaría el desarrollo de DCP. | spa |
| dc.description.abstract | Lupus nephritis and the problems in cognitive development presented by patients who suffer from it is a public health problem because lupus is known to affect multiple organs, including the nervous system, manifesting itself in psychiatric events or cognitive impairment. Objective: To evaluate the appearance of primary cognitive impairment in patients diagnosed with Lupus Nephritis belonging to Barranquilla (ATL, CO) during the year 2022. Methodology: A census of patients affiliated with a Foundation for patients with LN was carried out. The MoCA test was applied to evaluate the development of the DCP and this was crossed with the histopathological and sociodemographic results. Association measures such as Fischer's exact test and comparisons between groups with DPC and without DPC were performed. Results: A total of 30 patients who met the inclusion and exclusion criteria were evaluated. The average age was 38.11 years, the proliferative classes were the predominant (76.67%) The average MoCA Test score was 22.6±+4.49, 76.7% of the patients presented some degree of PCD; There was no difference between men and women for PCD, nor for histopathological class (p > 0.05). Education, Sex and Age were evaluated through a simple regression, finding that none of the three had a relationship with DCP (p: 0.05). Through an ANOVA, a difference was observed between the 3 levels of DCP (p: 0.0119), the concentration of CrSr vs. the DPC was modeled and an inverse significance was found, that is, the more CrSr increases, the MoCA score decreases, that is, the DPC is more marked. Conclusions: The presence of CPP in patients with LN is high compared to the proportion of those who have not developed it (7/10). The CrSr concentration was the determining factor for the development of PCD in patients with LN, that is, controlling this parameter would control the development of PCD. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/11470 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Nefritis lúpica | spa |
| dc.subject | Deterioro cognitivo primaria | spa |
| dc.subject | Test MoCA | spa |
| dc.subject | Creatinina sérica | spa |
| dc.subject | Lupus nephritis | eng |
| dc.subject | Primary cognitive impairment | eng |
| dc.subject | MoCA test | eng |
| dc.subject | Serum creatinine | eng |
| dc.title | Evaluación del deterioro cognitivo primario en pacientes con nefritis lúpica de Barranquilla (Atl, co) | spa |
| dc.type.driver | info:eu-repo/semantics/other | spa |
| dc.type.spa | Otros | spa |
| dcterms.references | Wallace ADJ. Manifestaciones clínicas y diagnóstico del lupus eritematoso sistémico en adultos. 2019;1–24. | spa |
| dcterms.references | Delgado N. Nefritis lúpica. Med infant. 2000;7(4):272–8. | spa |
| dcterms.references | Martínez GA, Gonzalez-Torres HJ, Martinez A. Quality of life of patients with lupic nephritis: the case of the colombian caribbean region. In: Lupus Science & Medicine [Internet]. 2017. p. A180 LP-A180. Available from: http://lupus.bmj.com/content/4/Suppl_1/A180.3.abstract | eng |
| dcterms.references | Allegri R, Roqué M. Deterioro Cognitivo, Alzheimer y otras Demencias. 2015. 172 p. | spa |
| dcterms.references | Chacón-Valenzuela E, Morros-González E, Vargas-Beltrán MP, Venegas-Sanabria LC, Gómez-Arteaga RC, Chavarro-Carvajal D, et al. Fragilidad cognitiva, un desafío en evolución. Univ Médica. 2019;60(3):1–11. | spa |
| dcterms.references | Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. 2004 Dec;107(1):1–16. | eng |
| dcterms.references | Reyes CR. Libro Deterioro Cognitivo. Panorama Agropecuario. 2015. | spa |
| dcterms.references | Deterioro cognitivo leve - Síntomas y causas [Internet]. Mayo Clinic. 2022. p. 2. Available from: https://www.mayoclinic.org/es-es/diseases-conditions/mild-cognitive-impairment/symptoms-causes/syc-20354578 | spa |
| dcterms.references | Arriola E, Carnero C, Freire A, López-Mogil R, López-Trigo JA, Manzano S, et al. Deterioro cognitivo leve en el adulto mayor. Documento de consenso. Sociedad Española de Geriatría y Gerontología. 2017. 1–36 p. | spa |
| dcterms.references | Vinet L, Zhedanov A. Evaluation of cognitive impairment and dementia - UpToDate Official. J Chem Inf Model. 2010 Nov;53:1689–99. | eng |
| dcterms.references | Larson EB. Risk factors for cognitive decline and dementia - UpToDate. Oct 2018. 2018;1–19. | eng |
| dcterms.references | Knopman DS, Demencia ALA. 374 - Deterioro cognitivo y demencia. 26th Editi. Goldman-Cecil. Tratado de medicina interna. Elsevier Espa8#241;a, S.L.U.; 2021. 2213–2216 p. | spa |
| dcterms.references | Impairment C, Factors R. Demencia y Deterioro Cognitivo, Factores de Riesgo y Prevención. (Dcl):1–19. | spa |
| dcterms.references | Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJPM, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: Meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100(2):657–66. | eng |
| dcterms.references | Clemente I, Solé - Padullés C, Bartrés Faz D. Marcadores genéticos relacionados con el déficit cognitivo en el envejecimiento. An Psicol. 2004;20(2):187–204. | spa |
| dcterms.references | Campdelacreu J. Enfermedad de Alzheimer y factores de riesgo ambientales. Rev Cubana Enferm [Internet]. 2017;33(1). Available from: http://www.revenfermeria.sld.cu/index.php/enf/article/view/1024/239 | spa |
| dcterms.references | Lee LA. 41 - Lupus eritematoso. Fourth Edi. DermatologÃa. Elsevier Espa8#241;a, S.L.U.; 2022. 662–680 p. | spa |
| dcterms.references | Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol [Internet]. 2015;11(6):329–41. Available from: http://www.nature.com/doifinder/10.1038/nrneph.2015.33 | eng |
| dcterms.references | Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) [Internet]. 2012 Jun;64(6):797–808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22556106 | eng |
| dcterms.references | Koutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. 2014; | eng |
| dcterms.references | Gurevitz SL, Snyder JA, Wessel EK, Frey J, Williamson BA. Systemic lupus erythematosus: A review of the disease and treatment options. Consult Pharm. 2013;28(2):110–21. | eng |
| dcterms.references | Zubair A, Frieri M. Lupus nephritis: Review of the LITERATURE. Curr Allergy Asthma Rep. 2013;13(6):580–6. | eng |
| dcterms.references | Viana De Queiroz M. Lupus Eritematoso Sistemico. Acta Med Port. 1994;7(6):343–8. | spa |
| dcterms.references | pe Corona-Sanchez EG. Lupus eritematoso sistémico: implicaciones de la inmunidad innata. El Resid. 2015;10(1):4–11. | spa |
| dcterms.references | Cervera R, Khamashta M a, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308. | eng |
| dcterms.references | Xu R, Li Q, Liu R, Shen J, Li M, Zhao M, et al. Association Analysis of the MHC in Lupus Nephritis. J Am Soc Nephrol. 2017 Nov;28(11):3383–94. | eng |
| dcterms.references | Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey‐Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400–12. | eng |
| dcterms.references | Medlin JL, Hansen KE, Fitz SR, Bartels CM. A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2016 Jun;45(6):691–7. | eng |
| dcterms.references | Hejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. Am J Clin Dermatol. 2016 Apr;17(2):135–46. | eng |
| dcterms.references | Kado R. Systemic Lupus Erythematosus for Primary Care. Prim Care Clin Off Pract. 2018 Jun;45(2):257–70. | eng |
| dcterms.references | Nutan F, Ortega-Loayza AG. Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options. J Investig Dermatology Symp Proc. 2017 Oct;18(2):S64–8. | eng |
| dcterms.references | Galindo M, Molina RA, Álvarez JLP. Lupus eritematoso sistémico (I). Etiopatogenia. Manifestaciones clínicas. Historia natural. Pruebas diagnósticas. Diagnóstico diferencial. Med - Programa Form Médica Contin Acreditado. 2017 Feb;12(25):1429–39. | spa |
| dcterms.references | Fava A, Petri M. Systemic lupus erythematosus : Diagnosis and clinical management. J Autoimmun. 2019;96(September 2018):1–13. | eng |
| dcterms.references | Acosta I, Avila G, Acosta M, Aquino A, Centurión O. Manifestaciones clínicas y laboratoriales en el Lupus eritematoso sistemico- LES. 2016;14(1). | spa |
| dcterms.references | Alonso M. Lupus eritematoso sistémico. Epidemiología y presentación clínica en el noroeste de España. UNIVERSIDAD DE CANTABRIA; 2017. | spa |
| dcterms.references | Ceccarelli F, Perricone C, Cipriano E, Massaro L, Natalucci F, Capalbo G, et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment. Semin Arthritis Rheum. 2017 Aug;47(1):53–64. | eng |
| dcterms.references | Kolasinski SL, Chi AS, Lopez-Garib AJ. Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis. Rheum Dis Clin North Am. 2016 Nov;42(4):711–32. | eng |
| dcterms.references | Miner JJ, Kim AHJ. Cardiac Manifestations of Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2014 Feb;40(1):51–60. | eng |
| dcterms.references | Kotkar KD, Said SM. Libman-Sacks Endocarditis in a Patient With Antiphospholipid Syndrome. Ann Thorac Surg. 2016 Jul;102(1):e31–2. | eng |
| dcterms.references | Samura T, Toda K, Yoshioka D, Nakamura T, Miyagawa S, Yoshikawa Y, et al. Libman-Sacks Endocarditis Due to Systemic Lupus Erythematosus Activation After Mitral Valve Plasty. Ann Thorac Surg. 2017 Aug;104(2):e109–11. | eng |
| dcterms.references | Chazal T, Kerneis M, Guedeney P, Haroche J, Mathian A, Rufat P, et al. Coronary artery disease in systemic lupus: A case-controlled angiographic study. Autoimmun Rev. 2020 Jan;19(1):102427. | eng |
| dcterms.references | Fernández-Nebro A, Rúa-Figueroa Í, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, et al. Cardiovascular Events in Systemic Lupus Erythematosus. Medicine (Baltimore). 2015 Jul;94(29):e1183. | spa |
| dcterms.references | Koo BS, Hong S, Kim YJ, Kim Y-G, Lee C-K, Yoo B. Lupus enteritis: clinical characteristics and predictive factors for recurrence. Lupus. 2015 May;24(6):628–32. | eng |
| dcterms.references | Brewer BN, Kamen DL. Gastrointestinal and Hepatic Disease in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2018 Feb;44(1):165–75. | eng |
| dcterms.references | Zhang F, Zhang J, Zhou L, Wang A-M, Li X. Intestinal pseudo-obstruction as the initial manifestation of systemic lupus erythematosus. Am J Emerg Med. 2019 Jan;37(1):176.e1-176.e2. | eng |
| dcterms.references | Chaudhury D, Qureshi A, Prasad S, Meena RK, Sharma S. Catatonia – An unusual presenting clinical manifestation of systemic lupus erythematosus. Reumatol Clínica. 2017 Jul;13(4):224–6. | eng |
| dcterms.references | Hanly JG. Attribution in the assessment of nervous system disease in SLE. Rheumatology. 2015 May;54(5):755–6. | eng |
| dcterms.references | Bortoluzzi A, Scirè CA, Bombardieri S, Caniatti L, Conti F, De Vita S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology. 2015 May;54(5):891–8. | eng |
| dcterms.references | Jafri K, Patterson SL, Lanata C. Central Nervous System Manifestations of Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2017 Nov;43(4):531–45. | eng |
| dcterms.references | Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014 Jun;10(6):338–47. | eng |
| dcterms.references | Ruiz-Irastorza G, Espinosa G, Frutos MA, Jiménez-Alonso J, Praga M, Pallarés L, et al. Diagnosis and treatment of Lupus nephritis: Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish society of internal medicine (SEMI) and the Spanish society of nephrology (S.E.N.). Nefrologia. 2012;32(SUPPL. 1):1–45. | eng |
| dcterms.references | Peña-Vargas W, Aroca-Martínez G, González-Torres HJ, Iglesia-Gamarra A, García-Tolosa R, Pérez-Padilla R, et al. Medición de la respuesta a la inducción y mortalidad en 414 pacientes con Nefritis Lúpica en la Región Caribe Colombiana. Arch Venez Farmacol y Ter. 2021;40(1):94–100. | spa |
| dcterms.references | Novillo Valdivieso MS, Ayala López IM, Mora Gonzalez MG, Hurtado Herdoiza LO. Diagnóstico y tratamiento de la nefritis lúpica. Recimundo. 2019;3(3):410–27. | spa |
| dcterms.references | Horta-Baas G, Camargo-Coronel A, Miranda-Hernández DG, Gónzalez-Parra LG, Romero-Figueroa M del S, Pérez-Cristóbal M. Renal Transplantation in Systemic Lupus Erythematosus: Comparison of Graft Survival With Other Causes of End-stage Renal Disease. Reumatol Clínica (English Ed. 2019 May;15(3):140–5. | eng |
| dcterms.references | Soliman WM, Sherif NM, Ghanima IM, EL-Badawy MA. Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus Erythematosus: Relation With Disease Activity and Lupus Nephritis. Reumatol Clínica (English Ed. 2020 Jul;16(4):255–61. | eng |
| dcterms.references | Miranda-Hernández D, Cruz-Reyes C, Angeles U, Jara LJ, Saavedra MA. Prognostic Factors for Treatment Response in Patients With Lupus Nephritis. Reumatol Clínica (English Ed. 2014 May;10(3):164–9. | eng |
| dcterms.references | Chowdhary VR. Broad Concepts in Management of Systemic Lupus Erythematosus. Mayo Clin Proc. 2017 May;92(5):744–61. | eng |
| dcterms.references | Coronado Alvarado CD, Gámez Saiz IL, Sotelo Cruz N. Características clínicas y comorbilidades de pacientes con lupus eritematoso sistémico en niños y adultos. Acta Pediátrica México. 2018;1(1):1. | spa |
| dcterms.references | Pedraza OL, Salazar AM, Sierra FA, Soler D, Castro J, Castillo P, et al. Pedraza, Salazar, Sierra, Soler, Castro, Castillo, Hernández, Piñeros, 2016 VALIDACIÓN MoCA bogota. Acta Medica Colomb. 2016;41:221–8. | spa |
| dcterms.references | Loureiro C, García C, Adana L, Yacelga T, Rodríguez-Lorenzana A, Maruta C. Use of the montreal cognitive assessment (MoCA) in Latin America: A systematic review. Rev Neurol. 2018 Jun;66(12):397–408. | eng |
| dcterms.references | Aguilera-Pickens G, Abud-Mendoza C. Manifestaciones neuropsiquiátricas en lupus eritematoso generalizado: bases fisiopatogénicas y terapéuticas. Reumatol Clínica [Internet]. 2013 Nov;9(6):331–3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1699258X13000843 | spa |
| dcterms.references | Castellano M, Bernarte M, Castellano CA, Favaro ML, Mateo VE. Deterioro cognitivo sin demencia en la insuficiencia renal crónica terminal. Datos de un centro argentino. Rev Nefrol Diálisis y Traspl. 2020;40(2):119–28. | spa |
| oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
| sb.programa | Especialización en Psiquiatría | spa |
| sb.sede | Sede Barranquilla | spa |